Riboscience LLC
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2012-01-01
- Employees
- 11
- Market Cap
- -
- Website
- https://www.riboscience.com
Evaluation of RBS2418 in Patients with Advanced, Metastatic, and Progressive Colorectal Cancer
Phase 2
Recruiting
- Conditions
- Metastatic Colorectal CancerAdvanced Colorectal Cancer
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-03-27
- Lead Sponsor
- Riboscience, LLC.
- Target Recruit Count
- 150
- Registration Number
- NCT06824064
- Locations
- 🇺🇸
University of California, Los Angeles, Los Angeles, California, United States
🇻🇳Tam Anh TP. Ho Chi Minh General Hospital, Ho Chi Minh, Ho Chi Minh City, Vietnam
🇻🇳Tam Anh, Ha Noi General Hospital, Ha Noi, Vietnam
Expanded Access RBS2418 Treatment
- Conditions
- Expanded Access in Pancreatic Cancer
- First Posted Date
- 2023-01-13
- Last Posted Date
- 2024-02-21
- Lead Sponsor
- Riboscience, LLC.
- Registration Number
- NCT05683470
Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors
- First Posted Date
- 2022-03-08
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- Riboscience, LLC.
- Target Recruit Count
- 64
- Registration Number
- NCT05270213
- Locations
- 🇺🇸
Norton Cancer Institute, Louisville, Kentucky, United States
🇺🇸Honor Health Research Institute, Scottsdale, Arizona, United States
🇺🇸University of Arizona, Tucson, Arizona, United States
© Copyright 2025. All Rights Reserved by MedPath